Oxford Biodynamics launches prostate screening test
EpiSwitch is designed for men with prostate cancer risk in the UK and is 94% accurate
Read More
Tag: EpiSwitch
Oxford BioDynamics signs deal to develop ASD biomarkers
Oxford BioDynamics, Italian research institute pair to develop biomarkers for autism spectrum disorder (ASD).
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
